Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within Two Premier Pain Clinics
Both of these prominent pain management practices are located in California and owned by Pain Management Specialists.
ROSELAND, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it has commenced sales of the CompuFlo® Epidural disposables at the Cypress Surgery Center in Santa Maria, California and the Galileo Surgery Center in San Luis Obispo. Both of these prominent pain management practices are located in California and owned by Pain Management Specialists.
Pain Management Specialists (PMS) is a group of specially trained physicians, dedicated to the evaluation and treatment of acute and chronic pain. Its physicians utilize the latest techniques and apply the most current theories, to provide patients with a comprehensive treatment plan, necessary to assist in their fight against pain.
Arjan Haverhals, CEO and president of Milestone Scientific, stated, “We continue to expand sales of our CompuFlo Epidural system within pain clinics across the U.S. The selection of our technology by these two clinics follows successful evaluation, reinforcing the safety, economic and efficiency benefits, as well as the improved patient experience.”
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2020. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact: David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: [email protected]
Tel: 212-671-1020
